• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

    4.970 -0.010 (-0.20%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 28, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 942,823
    Open 5.040
    Bid (Size) 4.850 (25)
    Ask (Size) 5.000 (25)
    Prev. Close 4.980
    Today's Range 4.870 - 5.189
    52wk Range 3.785 - 14.60
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Top movers in Wednesday's after hours session
    Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
    Via Chartmill
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga

    Performance

    YTD
    -44.7%
    -44.7%
    1 Month
    -12.0%
    -12.0%
    3 Month
    -23.3%
    -23.3%
    6 Month
    -9.8%
    -9.8%
    1 Year
    -22.5%
    -22.5%

    More News

    Read More
    Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
    From Candel Therapeutics
    Via GlobeNewswire
    How Is The Market Feeling About Candel Therapeutics?
    Via Benzinga
    Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients
    Via Benzinga
    Candel Therapeutics Shares Are Down Today: What's Going On?
    Via Benzinga
    Candel’s Final Survival Data From Lung Cancer Drug Trial Lifts Stock After-Hours, Fuels Retail Optimism
    Via Stocktwits
    Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
    From Candel Therapeutics
    Via GlobeNewswire
    Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week
    Via Stocktwits
    This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
    Via Benzinga
    Major Indexes Falter; Dow Drops Over 550 Points
    Via Talk Markets
    Topics Stocks Stocks / Equities
    Exposures US Equities
    Let's uncover which stocks are experiencing notable gaps during today's session.
    Via Chartmill
    Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice
    Via Stocktwits
    This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
    Via Benzinga
    Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call
    Via Stocktwits
    This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
    Via Benzinga
    Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
    From Candel Therapeutics
    Via GlobeNewswire
    Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
    From Candel Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga

    Frequently Asked Questions

    Is Candel Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Candel Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Candel Therapeutics, Inc. - Common Stock trade on?
    Candel Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Candel Therapeutics, Inc. - Common Stock?
    The ticker symbol for Candel Therapeutics, Inc. - Common Stock is CADL on the Nasdaq Stock Market
    What is the current price of Candel Therapeutics, Inc. - Common Stock?
    The current price of Candel Therapeutics, Inc. - Common Stock is 4.970
    When was Candel Therapeutics, Inc. - Common Stock last traded?
    The last trade of Candel Therapeutics, Inc. - Common Stock was at 04/28/25 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.